2019
Patient and Provider Variables Associated with Variation in the Systemic Treatment of Advanced Prostate Cancer.
Caram M, Wang S, Tsao P, Griggs J, Miller D, Hollenbeck B, Lin P, Mukherjee B. Patient and Provider Variables Associated with Variation in the Systemic Treatment of Advanced Prostate Cancer. Urology Practice 2019, 6: 234-242. PMID: 31276025, PMCID: PMC6605774, DOI: 10.1097/upj.0000000000000020.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerAndrogen signaling inhibitorsAdvanced prostate cancerFirst-line treatmentProstate cancerSystemic treatment of advanced prostate cancerDatabase of commercially insured patientsTreatment of advanced prostate cancerCastration-resistant prostate cancerSignaling inhibitorsPre-existing heart failureImproved overall survivalTreatment of menCommercially insured patientsSipuleucel-TRadium-223Overall survivalSystemic treatmentTreatment patternsNovel therapiesMedical oncologistsHeart failureMultivariate analysisProvider specialtyDocetaxel
2017
Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D
Caram M, Borza T, Min H, Griggs J, Miller D, Hollenbeck B, Mukherjee B, Skolarus T. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. JCO Oncology Practice 2017, 13: jop.2016.020206. PMID: 28628393, PMCID: PMC5555032, DOI: 10.1200/jop.2016.020206.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerHospital referral regionsProstate cancerMetastatic castration-resistant prostate cancer treatmentCastration-resistant prostate cancerProvider specialtyAdvanced prostate cancerMedicare Part DProstate cancer incidenceFood and Drug AdministrationMinority of providersYears of ageEnzalutamide prescriptionsMultilevel regression modelsMedicare Part D dataPart DEnzalutamideAbirateroneMedical oncologistsMedical oncologyEarly disseminationTreated menPart D dataCancer incidenceWorkforce densityEarly national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D.
Caram M, Borza T, Min H, Griggs J, Miller D, Hollenbeck B, Mukherjee B, Skolarus T. Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare Part D. Journal Of Clinical Oncology 2017, 35: 35-35. DOI: 10.1200/jco.2017.35.8_suppl.35.Peer-Reviewed Original ResearchAdvanced prostate cancerHospital referral regionsProstate cancerProvider specialtyAdvanced prostate cancer treatmentProstate cancer incidenceProstate cancer treatmentMedicare Part DEnzalutamide prescriptionsFood & Drug AdministrationMedicare Part D dataEnzalutamideMinority of providersAbirateroneMedical oncologistsOral medicationsMedical oncologyEarly disseminationTreated menPart D dataCancer incidenceDrug AdministrationCancer treatmentMultilevel regression modelsPart D